Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
290 enrolled
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Phase 1/2 Recruiting
74 enrolled
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Phase 3 Recruiting
320 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
698 enrolled
IDeate-Prostate02
Phase 1/2 Recruiting
360 enrolled
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Phase 2/3 Recruiting
613 enrolled
MK-5684-01A
Phase 1/2 Recruiting
220 enrolled
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Phase 2 Recruiting
60 enrolled
MK-2400-001
Phase 3 Recruiting
1,440 enrolled
TroFuse-033
Phase 3 Recruiting
1,123 enrolled
KLK2-PASenger
Phase 3 Recruiting
800 enrolled
RASolve 301
Phase 3 Recruiting
420 enrolled
DE-01
Phase 3 Recruiting
600 enrolled
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Phase 2 Recruiting
20 enrolled
EmpowHER 208
Phase 2 Recruiting
125 enrolled
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
Phase 2 Recruiting
34 enrolled
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
Phase 1 Recruiting
20 enrolled
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
572 enrolled
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Phase 2 Recruiting
70 enrolled
(NeoScorch HN)
Phase 2 Recruiting
75 enrolled
ARTEMIA
Phase 3 Recruiting
363 enrolled
InavoPC
Phase 2 Recruiting
100 enrolled
MEVPRO-1
Phase 3 Recruiting
600 enrolled
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3 Recruiting
1,100 enrolled
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Phase 3 Recruiting
1,260 enrolled
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Phase 2 Recruiting
131 enrolled
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Phase 2 Recruiting
82 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Phase 1/2 Recruiting
366 enrolled
Intravesical Gem/Doce in Patients With NMIBC
Phase 2 Recruiting
25 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3 Recruiting
540 enrolled
KEYNOTE-365
Phase 1/2 Recruiting
1,200 enrolled
TARMAC
Phase 2 Recruiting
85 enrolled
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Phase 2 Recruiting
74 enrolled
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Phase 1 Recruiting
277 enrolled
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2 Recruiting
230 enrolled
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Phase 1/2 Recruiting
98 enrolled
OPTION-DDR
Phase 3 Recruiting
236 enrolled
TROPION-Lung17
Phase 3 Recruiting
400 enrolled
Fern-EC-01
Phase 3 Recruiting
480 enrolled
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Phase 3 Recruiting
740 enrolled
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Phase 2 Recruiting
49 enrolled
A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 Recruiting
101 enrolled
rechARge
Phase 3 Recruiting
960 enrolled
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Phase 1/2 Recruiting
594 enrolled
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Phase 3 Recruiting
387 enrolled
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
51 enrolled